4D Molecular Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- 4D Molecular Therapeutics's estimated annual revenue is currently $17M per year.
- 4D Molecular Therapeutics received $0.5M in venture funding in September 2018.
- 4D Molecular Therapeutics's estimated revenue per employee is $110,195
- 4D Molecular Therapeutics's total funding is $175M.
- 4D Molecular Therapeutics's current valuation is $546M. (January 2022)
Employee Data
- 4D Molecular Therapeutics has 154 Employees.
- 4D Molecular Therapeutics grew their employee count by -1% last year.
4D Molecular Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | Executive Business Partner, CEO Office | Reveal Email/Phone |
2 | CFO | Reveal Email/Phone |
3 | CEO, Co-Founder | Reveal Email/Phone |
4 | Chief Staff, Co-Founder | Reveal Email/Phone |
5 | VP, Clinical Operations & Data Management | Reveal Email/Phone |
6 | VP, Regulatory Affairs, Quality and GxP Compliance | Reveal Email/Phone |
7 | VP Information Technology | Reveal Email/Phone |
8 | SVP | Reveal Email/Phone |
9 | Associate Director Program Management | Reveal Email/Phone |
10 | Director, Vector and Product Development | Reveal Email/Phone |
4D Molecular Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is 4D Molecular Therapeutics?
The mission of 4D Molecular Therapeutics is to design and develop transformative gene therapy products using our proprietary technology to create novel adeno-associated virus variants to be utilized as treatments for serious unmet medical conditions. Our products are unlocking the full potential of gene therapy to treat, and potentially cure, genetic diseases. A large number of patients and diseases, who previously were not treatable by gene therapy, will be addressable by 4D products. 4D has one of the deepest and most diverse product pipelines in the gene therapy field. Adeno-associated virus (AAV) vectors have emerged as a favored delivery vehicle for gene therapy in the human body. They can deliver the genes for therapeutic proteins to accessible tissues in the body and are generally considered safe. Several AAV gene therapy products are in late-stage clinical development, and one product is approved in the EU (Glybera, Uniqure). However, these first-generation AAV vectors have limited utility for the majority of diseases. Many of these common AAV were discovered as laboratory contaminants and monkey infections, for example; they have not been customized as targeted medicines. In contrast, 4D customized AAV vectors, and the products made from them, are designed to unlock the full potential of gene therapy. Through 4D's Therapeutic Vector Evolution, we are able to create customized vectors solutions to overcome the hurdles identified with first-generation AAV vectors. 4D is creating the ultimate gene therapy products to cure genetic diseases using new customized delivery vehicles (vectors) to shuttle genes into the cells in any organ in the body. This 4D library of vectors will soon include several for the liver, several for the brain, several for the heart, the eye, muscle, and so on. Doctors will be able to hand pick a vector for any patient based on the organ that is diseased.
keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power$175M
Total Funding
154
Number of Employees
$17M
Revenue (est)
-1%
Employee Growth %
$546M
Valuation
N/A
Accelerator
4D Molecular Therapeutics News
InvestorsObserver is giving 4D Molecular Therapeutics Inc (FDMT) an Analyst Rating Rank of 73, meaning FDMT is ranked higher by analysts...
4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-710, an A101 AAV Vector-based, Aerosol-delivered...
EMERYVILLE, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics...
EMERYVILLE, Calif.--(BUSINESS WIRE)--4D Molecular Therapeutics (4DMT), a clinical-stage leader in the development of precision-guided AAV gene medicines based on directed evolution, announced the closing of its $75 million Series C financing. The round was led by Viking Global Investors, with pa ...
Genetic Modification Therapies Market Business Growth and Top Key Players like: 4D Molecular Therapeutics, Abeona Therapeutics, Allergan, ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $67.9M | 158 | 22% | $216M |
#2 | $18.1M | 165 | 1% | $95.3M |
#3 | $12.2M | 167 | 11% | $26.1M |
#4 | $27.9M | 169 | 21% | N/A |
#5 | $34.1M | 176 | 3% | $74M |
4D Molecular Therapeutics Funding
Date | Amount | Round | Lead Investors | Reference |
---|---|---|---|---|
2017-09-20 | $3.0M | Undisclosed | Cystic Fibrosis Foundation Therapeutics Inc | Article |
2018-09-06 | $90.0M | B | Viking Global Investors | Article |
2018-09-10 | $0.5M | Undisclosed | CureDuchenne Ventures | Article |